An interaction between the interleukin-6-174G>C gene variant and urinary protein excretion influences plasma oxidative stress in subjects with type 2 diabetes

被引:28
作者
Stephens, Jeffrey W. [1 ,2 ]
Hurel, Steven J. [2 ]
Acharya, Jayshree [1 ]
Humphries, Steve E. [1 ]
机构
[1] Royal Free & Univ Coll London Med Sch, British Heart Fdn Labs, Ctr Cardiovasc Genet, London WC1E 6JF, England
[2] UCL Hosp, Dept Endocrinol & Diabet, London W1T 3AA, England
关键词
Diabetes; Gene variant; Interleukin-6; Oxidative stress; Proteinuria;
D O I
10.1186/1475-2840-3-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Microalbuminuria and subsequent progression to proteinuria and nephropathy is associated with increased oxidative stress, increased inflammatory cytokines and increased cardiovascular (CVD) risk. The common functional IL-6 -174G > C gene variant is also associated with elevated levels of inflammatory cytokines and CVD risk. Methods: The aim of this study was to examine the association between the IL-6 -174G > C gene variant with plasma total antioxidant status (TAOS) in 552 subjects with type 2 diabetes in relation to urinary protein excretion. Results: In subjects free from CVD, there was a significant interaction between urinary protein excretion (normoalbuminuria/microalbuminuria/proteinuria) and the -174C allele (compared to -174GG) in determining plasma TAOS (p value for interaction = 0.03). In the -174C allele carriers there was a significant association between plasma TAOS and urinary protein excretion: normalbuminuria v microalbuminuria v proteinuria: 44.30% +/- 11.32 vs. 39.74% +/- 14.83 vs. 37.93% +/- 16.42, ANOVA p = 0.025. In those with CVD, no interaction or association was observed with the -174C allele (p = 0.246). Conclusion: The IL-6 -174G > C gene variant is associated with differences in plasma oxidative stress in response to altered protein excretion in subjects with type 2 diabetes.
引用
收藏
页数:6
相关论文
共 27 条
  • [1] Alberti KGMM, 1998, DIABETIC MED, V15, P535, DOI 10.1002/(SICI)1096-9136(199807)15:7<535::AID-DIA670>3.3.CO
  • [2] 2-H
  • [3] Interleukin-6 gene -174G &gt; C and -572G &gt; C promoter polymorphisms are strong predictors of plasma -: Interleukin-6 levels after coronary artery bypass surgery
    Brull, DJ
    Montgomery, HE
    Sanders, J
    Dhamrait, S
    Luong, L
    Rumley, A
    Lowe, GDO
    Humphries, SE
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (09) : 1458 - 1463
  • [4] Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients
    Clermont, G
    Lecour, S
    Lahet, JJ
    Siohan, P
    Vergely, C
    Chevet, D
    Rifle, G
    Rochette, L
    [J]. CARDIOVASCULAR RESEARCH, 2000, 47 (03) : 618 - 623
  • [5] INTERLEUKIN-6 - AN AUTOCRINE REGULATOR OF MESANGIAL CELL-GROWTH
    COLEMAN, DL
    RUEF, C
    [J]. KIDNEY INTERNATIONAL, 1992, 41 (03) : 604 - 606
  • [6] ELECTROPHORESIS FOR GENOTYPING - MICROTITER ARRAY DIAGONAL GEL-ELECTROPHORESIS ON HORIZONTAL POLYACRYLAMIDE GELS, HYDROLINK, OR AGAROSE
    DAY, INM
    HUMPHRIES, SE
    [J]. ANALYTICAL BIOCHEMISTRY, 1994, 222 (02) : 389 - 395
  • [7] The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
    Fishman, D
    Faulds, G
    Jeffery, R
    Mohamed-Ali, V
    Yudkin, JS
    Humphries, S
    Woo, P
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) : 1369 - 1376
  • [8] Harrison D, 2003, AM J CARDIOL, V91, p7A
  • [9] BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6
    HIRANO, T
    AKIRA, S
    TAGA, T
    KISHIMOTO, T
    [J]. IMMUNOLOGY TODAY, 1990, 11 (12): : 443 - 449
  • [10] HORII Y, 1993, KIDNEY INT, V43, pS71